Infliximab Intravenous (Remicade®, Inflectra®, Renflexis®, Avsola™, Infliximab)

Covers IV infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™) for the listed FDA‑approved and compendial off‑label indications (e.g., Crohn’s, ulcerative colitis, RA, PsA, plaque psoriasis, ankylosing spondylitis, Behçet’s, GVHD, hidradenitis suppurativa, uveitis, JIA, etc.) and excludes use that does not meet the indication‑specific criteria. Key requirements include indication‑specific minimum ages (commonly ≥18 or ≥6 for pediatric indications), required prior/step therapies, prescriber specialty or specialist consultation, documentation of prior trials and dosing, and objective evidence of clinical benefit for reauthorization (patients generally must be established on infliximab for specified minimum durations, often ≥6 months).

"Crohn's disease"

Sign up to see full coverage criteria, indications, and limitations.